(Bloomberg) -- UnitedHealth Group Inc., the biggest U.S. health insurer by sales, picked Gilead Sciences Inc.’s Harvoni as its preferred hepatitis C treatment, according to a person familiar with the matter.
The decision applies to UnitedHealth’s fully insured commercial customers, as well as to Medicaid and Medicare members. The Minnetonka, Minnesota-based insurer has about 45 million U.S. health-plan customers, though not all follow the company’s drug picks.
Read more...
Showing posts with label UnitedHealth. Show all posts
Showing posts with label UnitedHealth. Show all posts
Wednesday, January 28, 2015
Subscribe to:
Posts (Atom)